Thromboangiitis Obliterans with Rest Pain or Trophic Lesions When Prior Surgical Treatment Has Not Achieved Pain Relief or Ulcer Healing
This protocol addresses patients with Thromboangiitis obliterans (Buerger's disease) in an advanced stage, presenting with rest pain of the extremities or trophic lesions — including ischemic ulcers and gangrene — who have not responded adequately to an earlier line of surgical or procedural management.
Clinical Scenario
The patient presents with rest pain in the extremities or established trophic changes — ischemic ulcers or gangrene — signalling critical limb ischaemia within the context of Thromboangiitis obliterans.
Prior Treatment Line — Goals Not Achieved
The previous management approach — which may have included lumbar sympathectomy, infrainguinal bypass, omentopexy, or the Ilizarov technique — did not meet the expected targets of pain relief, ulcer healing, and improved claudication distance. This protocol defines the structured next step after that shortfall.
Next-Line Approach (Partial Overview)
When surgical approaches have not achieved adequate relief, the protocol moves to advanced interventions — including neuromodulatory techniques and regenerative or cell-based therapies. Targeted pharmacological options are also part of the structured algorithm. The full selection criteria, sequencing, and treatment details are available in the complete protocol.
Treatment Goals
- Pain relief and healing of trophic ulcers
- Improved peripheral microcirculation
- Improved pain-free walking distance
- Improved transcutaneous partial oxygen pressure at 12 weeks
- Improved pain rating and claudication walking distance at 6 months
References
- In a randomized study, 152 patients with Buerger's disease presenting with rest pain, with or without trophic changes, received intravenous iloprost or placebo.
- A study by Donas et al. in TAO patients, it was seen that regional perfusion index improved significantly after SCS though patient continued to smoke.
- It was shown that it not only helps relieve pain but also has a role in increasing peripheral microcirculation, thus, increasing limb survival, healing of trophic ulcers, and avoidance of amputation.
- Many studies have shown efficiency of autologous bone marrow cell injections into ischemic limbs.
- During the 12-week observation after cell therapy, the Wong-Baker FACES pain rating scale, transcutaneous partial oxygen pressure, total or pain-free walking distance, and ulcer size serially improved in all patients.
- At 6 months, significant improvement was noted on pain rating scales and in claudication walking distance.
DOI: 10.1155/2013/156905
View source ↗